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To the Editor Recently, Ząbczyk et al 1 have presented an interesting overview of studies on fibrin clot structure and an in vitro measurement of fibrin clot permeability in such clinical conditions as stroke, myocardial infarction, and some other diseases associated with an elevated risk of thrombosis. The authors concluded that assays testing clot properties may improve identification of patients at high thromboembolic risk. Because in their extensive overview the authors omitted some data and did not discuss prothrombotic conditions associated with systemic inflammatory diseases, I would like to address these issues and refer to a study showing unfavorably altered fibrin clot properties, including lower clot permeability, faster clot formation, thicker fibrin fibers, and prolonged fibrinolysis in patients with rheumatoid arthritis (RA).
2 It was found that clot permeability in these patients inversely correlated with C -reactive protein and fibrinogen levels and with disease activity measured by the Disease Activity Score 28.
Currently, there is strong evidence for the interaction between the systemic inflammatory state in RA and the hemostatic system, which leads to a hypercoagulable state and increases thromboembolic and cardiovascular risk in these patients.
3 However, alteration of fibrin clot properties associated with disease activity was reported for the first time in 2010 by Kwaśny -Krochin et al.
2 Several factors contribute to the prothrombotic state in active RA, including inflammatory mediators and elevated levels of fibrinogen, D -dimers, tissue plasminogen activator, and plasminogen activator inhibitor 1.
3 An increased risk of thrombosis reported in RA is at least in part determined by elevated blood levels of factor VIII (FVIII).
4 Simulations of thrombin generation suggest that blood plasma composition, that is, elevated FVIII levels, partly counterbalanced by free tissue factor pathway inhibitor (TFPI) derived from the damaged endothelium, may accelerate coagulation. It was also reported that disease activity positively correlated with FV, FVIII, FIX, FX, antithrombin, and free TFPI levels, while it correlated negatively with protein Z levels.
4
As reported by Ząbczyk et al, 1 the use of medications may alter fibrin clot permeability in
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